TY - JOUR
T1 - Towards improvement of covalent neuraminidase inhibitors with anomeric substitution
AU - Vavricka, Christopher J.
AU - Matsumoto, Tatsuma
AU - Kiyota, Hiromasa
N1 - Funding Information:
Prof. Joseph Germana) and Ph.D. degree (2009, biochemistry, Prof. Jianyong Li) from Virginia Polytechnic and State University (Virginia Tech). He continued researching enzyme structures as an International Young Scientist Research Fellow and later as Associate Professor under the supervision of Prof. George F. Gao at the Chinese Academy of Sciences. After meeting and collaborating with many Japanese Influenza Researchers, Chris was accepted as a JSPS International Postdoctoral Researcher in the laboratory of Prof. Hiromasa Kiyota at Okayama University. Chris is now focusing on enzyme engineering as a Project Assistant Professor at the Graduate School of Science, Technology and Innovation of Kobe University (Prof. Tomohisa Hasunuma). His research on developing mechanism-based inhibitors, together with Professor Kiyota, is supported by JSPS KAKENHI (V18K065770), and Kato Memorial Bioscience Foundation.
Publisher Copyright:
© 2020 FCCA (Forum: Carbohydrates Coming of Age).
PY - 2020
Y1 - 2020
N2 - Neuraminidase (NA) inhibitors are effective at treating and preventing infections caused by epidemic and pandemic influenza viruses. The first generation of influenza NA inhibitors were inspired by the structure of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid, a putative oxocarbenium ion transition state analogue. As a next-generation approach to influenza NA inhibitor design, irreversible inhibitors targeting influenza NA Tyr406 are now being explored. After proving the concept that influenza NA can be irreversibly inhibited by difluorosialic acids, substitution of the anomeric carboxy group was examined as a second novel strategy. Anomeric sulfo analogues of sialic acid (N-acetylneuraminic acid, NANA) were thereby synthesized and found to inhibit influenza NA with higher potency relative to that of the corresponding anomeric carboxy and phosphono compounds, via enhanced electrostatic interactions with the NA active site triarginyl cluster. The combination of these two novel approaches is now being pursued to produce improved irreversible NA inhibitors.
AB - Neuraminidase (NA) inhibitors are effective at treating and preventing infections caused by epidemic and pandemic influenza viruses. The first generation of influenza NA inhibitors were inspired by the structure of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid, a putative oxocarbenium ion transition state analogue. As a next-generation approach to influenza NA inhibitor design, irreversible inhibitors targeting influenza NA Tyr406 are now being explored. After proving the concept that influenza NA can be irreversibly inhibited by difluorosialic acids, substitution of the anomeric carboxy group was examined as a second novel strategy. Anomeric sulfo analogues of sialic acid (N-acetylneuraminic acid, NANA) were thereby synthesized and found to inhibit influenza NA with higher potency relative to that of the corresponding anomeric carboxy and phosphono compounds, via enhanced electrostatic interactions with the NA active site triarginyl cluster. The combination of these two novel approaches is now being pursued to produce improved irreversible NA inhibitors.
KW - Anomeric sulfonate
KW - Irreversible NA inhibitors
KW - Neuraminidase
KW - Sialidase
UR - http://www.scopus.com/inward/record.url?scp=85078855282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078855282&partnerID=8YFLogxK
U2 - 10.4052/tigg.1801.1E
DO - 10.4052/tigg.1801.1E
M3 - Short survey
AN - SCOPUS:85078855282
SN - 0915-7352
VL - 32
SP - E1-E5
JO - Trends in Glycoscience and Glycotechnology
JF - Trends in Glycoscience and Glycotechnology
IS - 185
ER -